Related references
Note: Only part of the references are listed.Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants
S. Hartnack et al.
ZOONOSES AND PUBLIC HEALTH (2008)
Smallpox vaccine stability after maintenance at temperatures not recommended for shipping
KN Lee et al.
VACCINE (2006)
Ocular vaccinia infection in laboratory worker, Philadelphia, 2004
FMT Lewis et al.
EMERGING INFECTIOUS DISEASES (2006)
Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004
JJ Sejvar et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Stability of diluted smallpox vaccine under simulated clinical conditions
RL Kline et al.
VACCINE (2005)
Reactions to small pox vaccine in naive and previously-vaccinated individuals
C Auckland et al.
VACCINE (2005)
Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age
RE Eckart et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Laboratory-acquired vaccinia infection
CG Wlodaver et al.
JOURNAL OF CLINICAL VIROLOGY (2004)
Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax
FK Newman et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Laboratory acquired infection with recombinant vaccinia virus containing an immunornodulating construct
M Mempel et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
Brief report: Human infection due to recombinant vaccinia-rabies glycoprotein virus
CE Rupprecht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques
KJ Stittelaar et al.
VACCINE (2001)
Share Paper
